Elevated whole blood chemiluminescence in patients with systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 23, Issue 2, 2005, Pages 173-179

  Luczynska, Maria ^a   Szkudlarek, Urszula ^a   Dziankowska Bartkowiak, Bozena ^a   Waszczykowska, Elzbieta ^a   Kasielski, Marek ^a   Jozefowicz Okonkwo, Grazyna ^a   Nowak, Dariusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chemiluminescence; Interstitial lung disease; Oxidative stress; Systemic sclerosis

Indexed keywords

ALBUMIN; AUTOANTIBODY; BILIRUBIN; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; HEMOGLOBIN; PREDNISONE; REACTIVE OXYGEN METABOLITE; URIC ACID;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BODY MASS; CHEMOLUMINESCENCE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; DRUG EXPOSURE; ENDOTHELIUM; ERYTHROCYTE COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; LEUKOCYTE COUNT; LUNG FUNCTION TEST; MALE; MONOCYTE; OXIDATIVE STRESS; PHAGOCYTE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RESIDUAL VOLUME; SYSTEMIC SCLEROSIS; TISSUE DEGENERATION;

ADOLESCENT; ADULT; AGED; BREATH TESTS; CARBON MONOXIDE; CELLS, CULTURED; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUMINESCENT MEASUREMENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; PHAGOCYTES; PREDNISONE; PULMONARY DIFFUSING CAPACITY; REACTIVE OXYGEN SPECIES; SCLERODERMA, SYSTEMIC;

EID: 18644370015     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. HERRICK AL, MATUCCI-CERINIC M: The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001; 19: 4-8.
2. SIMININI G, PIGNONE A, GENERINI S et al.: Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 2000; 155: 1-15.
3. SOLANS R, MOTTA C, SOLA R et al.: Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 2000; 43: 894-900.
4. SIMONINI G, MATUCCI-CERINIC M, GENERINI S et al.: Oxidative stress in systemic sclerosis. Mol Cell Biochem 1999; 196: 85-91.
5. MEEHAN R, SPENCER R: Systemic sclerosis. Immunology and Allergy Clinics of North America 1993; 13: 313-34.
6. KALIN R, RIGHI A, DEL ROSSO A et al.: Activin, a grape seed-derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. Free Radic Res 2002; 36: 819-25.
7. STEIN CM, TANNER SB, AWAD JA, ROBERTS LJ 2nd, MORROW JD: Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996; 39: 1146-50.
8. KOVACS IB, MEYRICK THOMAS RH, MACKAY AR, RUSTIN MH, KIRBY JD: Increased chemiluminescence of polymorphonuclear leucocytes from patients with progressive systemic sclerosis. Clin Sci 1986; 70: 257-61.
9. SAMBO P, JANNINO L, CANDELA M et al.: Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999; 112: 78-84.
10. SAUGSTAD OD: Role of xanthine oxidase and its inhibitor in hypoxia: Reoxygenation injury. Pediatrics 1996; 98: 103-7.
11. CZIRJAK L, DANKO K, SIPKA S, ZEHER M, SZEGEDI G: Polymorphonuclear neutrophil function in systemic sclerosis. Ann Rheum Dis 1987; 46: 302-06.
12. MASLEN CL, HALL ND, WOOLF AD, MADDISON PJ: Enhanced oxidative metabolism of neutrophils from patients with systemic sclerosis. Br J Rheumatol 1987; 26: 113-7.
13. WATSON F, ROBINSON JJ, EDWARDS SW: Neutrophil function in whole blood and after purification: changes in receptor expression, oxidase activity and responsiveness to cytokines. Biosci Rep 1992; 12: 123-33.
14. REBECCHI IM, FERREIRA NOVO N, JULIAN Y, CAMPA A: Oxidative metabolism and release of myeloperoxidase from polymorphonuclear leukocytes obtained from blood sedimentation in a Ficoll-Hypaque gradient. Cell Biochem Funct 2000; 18: 127-32.
15. MEYRICK THOMAS RH, RADEMAKER M et al.: Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol 1987; 117: 237-41.
16. KOPPRASCH S, GRAESSLER J, KOHL M, BERGMANN S, SCHRÖDER HE: Comparison of circulating phagocyte oxidative activity measured by chemiluminescence in whole blood and isolated polymorphonuclear leukocytes. Clin Chim Acta 1996; 253: 145-57.
17. KUKOVETZ EM, BRATSCHITSCH G, HOFER HP, EGGER G, SCHAUR RJ: Influence of age on the release of reactive oxygen species by phagocytes as measured by a whole blood chemiluminescence assay. Free Radical Biol Med 1997; 22: 433-38.
18. MASI AT, RODNAN GP, MEDSGER TA et al.: Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum 1980; 23: 581-90.
19. Le ROY EC, BLACK CM, FLEISCHMAYER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-05.
20. CLEMENTS P, LACHENBRUCH P, SIEBOLD J et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
21. WELLS AU, HANSELL DM, CORRIN B et al.: High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47: 738-42.
22. American Thoracic Society: Standardization of spirometry 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36.
23. Single-breath carbon monoxide diffusing capacity (transfer factor): Recommendations for a standard technique - 1995 Update. Am J Respir Crit Care Med 1995; 152: 2185-98.
24. QUANJER PH, TAMMELING GJ, COTES JE, PEDERSEN OF, PESLIN R, YERNAULT JC: Lung volumes and forced ventilatory flows. Report working party standardization of lung European Respiratory Society. Eur Respir J 1993; 6 (Suppl. 16): 5-40.
25. CARPO RO, MORRIS AH: Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981; 123: 185-9.
26. SZKUDLAREK U, LUCZYNSKA M, KASIELSKI M, KAUCKA S, NOWAK D: Exhaled hydrogen peroxide correlates with the release of reactive oxygen species by blood phagocytes in healthy subjects. Respir Med 2003; 97: 718-25.
27. 2 produced by human neutrophils during the respiratory burst. Analytic Biochem 1987; 165: 371-8.
28. TARPEY MM, FRIDOVICH I: Methods of detection of vascular reactive oxygen species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 2001; 89: 224-36.
29. CZAUDERNA M, KOWALCZYK J: Simultaneous measurement of allantoin, uric acid, xanthine and hypoxanthine in blood by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 704: 89-98.
30. MIESEL R, MURPHY MP, KROGER H: Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 1996; 25: 161-9.
31. BENZIE IFF, STRAIN JJ: The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP assay. Anal Biochem 1996; 23: 970-76.
32. 2-halide system and stimulated polymorphonuclear leukocytes. Exp Pathol 1991; 42: 47-58.
33. HASEGAWA M, FUJIMOTO M, KIKUCHI K, TAKEHARA K: Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997; 24: 663-5.
34. IHN H, SATO S, FUJIMOTO M, KIKUCHI K, TAKEHARA K: Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 287:1 93-7.
35. GOUGEROT-POCIDALO MA, el BENNA J, ELBIM C, CHOLLET-MARTIN S, DANG MC: Regulation of human neutrophil oxidative burst by pro- and anti-inflammatory cytokines. J Soc Biol 2002; 196: 37-46.
36. PEAKE JM: Exercise-induced alterations in neutrophil degranulation and respiratory burst activity: possible mechanisms of action. Exerc Immunol Rev 2002; 8: 49-100.
37. CACHIA O, BENNA JE, PEDRUZZI E, DESCOMPS B, GOUGEROT-POCIDALO MA, LEGER CL: Alpha-tocopherol inhibits the respiratory burst in human monocytes. Attenuation of p47 (phox) membrane translocation and phosphorylation. J Biol Chem 1998; 273: 32801-5.
38. 2 production and elastase release in human neutrophils. Pharmacol Toxicol 1996; 79: 312-7.
39. van TITS LJ, DEMACKER PN, de GRAAF J, HAK-LEMMERS HL, STALENHOEF AF: α-Tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals. Am J Clin Nutr 2000; 71 : 458-64.
40. HERBACZYNSKA-CEDRO K, WARTANOWICZ M, PANCZENKO-KRESOWSKA, B, CEDRO K, KLOSIEWICZ-WASEK B, WASEK W: Inhibitory effect of vitamins C and E on the oxygen free radical production in human polymorphonuclear leukocytes. Eur J Clin Invest 1994; 24: 316-9.
41. HERBACZYNSKA-CEDRO K, KLOSIEWICZ-WASEK B, CEDRO K, WASEK W, PANCZENKO-KRESOWSKA B, WARTANOWICZ M: Supplementation with vitamins C and E suppresses leukocyte oxygen free radical production in patients with myocardial infarction. Eur Heart J 1995; 16: 1044-9,
42. OKUDA K, TADOKORO I, NOGUCHI Y: The metabolic and phagocytic activities of leukocytes from patients receiving corticosteroid and radiation therapy, and patients with bacterial infections. Jpn J Microbiol 1975; 19: 105-13.
43. VARAI G, EARLE L, JIMENEZ SA, STEINER RM, VARGA J: A pilot study of intermittent intravenous cyclpohosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25: 1325-9.
44. CLEMENT A, CHADELAT K, MASLIAH J et al.: A controlled study of oxygen metabolite release by alveolar macrophages from children with interstitial lung disease. Am Rev Respir Dis 1987; 136: 1424-8.
45. MATAMOROS MC, WALKER BK, Van DYKE K, VAN DYKE CJ: Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes Pharmacology 1983; 27: 29-39.
46. LUCZYNSKA M, SZKUDLAREK U, DZIANKOWSKA-BARTKOWIAK B et al.: Elevated exhalation of hydrogen peroxide in patients with systemic sclerosis. Eur J Clin Invest 2003; 33: 274-9.